in addiction research, and focus on novel, underserved, neglected, complex, or intractable aspects of the addiction phenomenon. How novel is the concept? Does it address important basic or clinical features/effects that are not currently or adequately addressed and/or with a fresh perspective?

2. Feasibility (5 points): Ideas, concepts, and the approaches, measures and systems derived from them must be rooted on a rational, scientific or otherwise cogent background that would guarantee a modicum of feasibility given the current challenges and state of the art in the field of addiction. How well does the research agenda describe the gaps in the relevant areas of science that need to be addressed by this new approach/concept to be achieved and implemented? Does the agenda describe a logical, feasible plan and timeframe for addressing those gaps?

3. Importance of the question being addressed/likelihood of impact (5 points): How effective would the successful completion of the project be in addressing addiction, enhancing prevention, or improving clinical outcomes? How well does it consider factors relevant to the ultimate success of the concept? How well does it harness innovations from other fields to the existing addiction knowledge base toward advancing drug abuse and addiction research?

Scores from each criterion will be weighted equally. The score for each submission will be the sum of the scores from each of the 5 voting judges, for a maximum of 75 points. NIDA reserves the right to make an award to submissions scoring less than 75 points if NIDA deems any sufficiently meritorious. All submissions will be held until after the deadline is reached and evaluated. Final recommendations will be determined by electronic (majority) vote of the judges.

Challenge Judges

Dr. Nora Volkow, Director, National Institute on Drug Abuse (NIDA)—Ex Officio
Dr. Roger Little, Deputy Director, Division of Basic Neuroscience and Behavioral Research, NIDA
Dr. David Epstein, Associate Scientist, Intramural Research Program, NIDA
Dr. David Liu, Team Leader, Medical Officer, Center for Clinical Trials Network, NIDA
Dr. Maureen Boyle, Chief, Science Policy Branch, Office of Science Policy and Communication, NIDA
Dr. Meyer D. Glantz, Associate Director for Science, Division of Epidemiology, Services, and Prevention Research
Dr. Ruben Baler, Health Scientist Administrator, Science Policy Branch, Office of Science Policy and Communication, NIDA
Dr. Steve Grant, Chief, Clinical Neuroscience Branch, Division of Clinical Neuroscience and Behavioral Research, NIDA
Dr. Philip Krieter, Pharmacologist, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, NIDA
Dr. Gerald McLaughlin, Chief, Scientific Review Branch, Division of Extramural Research, NIDA

Dated: May 11, 2015.

Nora D. Volkow,
Director, National Institute on Drug Abuse, National Institutes of Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be held on 06/18/2015–06/19/2015 instead of 06/17/2015–06/18/2015. The meeting time and location remains the same. The meeting is closed to the public.

Dated: May 19, 2015.

Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy.